Sarepta Therapeutics Inc (SRPT) - Market Cap to Earnings

Corporate emblem and logo of Sarepta Corp (SRPT)

Sarepta Therapeutics, Inc. (SRPT) relies on ultra-precise cryo-logistics for the delivery of gene therapies, ensuring high margins. The company's P/E valuation helps identify the business's real value, where -13.60 shows the value of this parameter. Douglas Ingram's R&D-focused strategy strengthens its position in muscular dystrophy therapy, while growing demand for orphan drugs expands the customer base.

SRPT (Sarepta Corp) Price to Earnings Ratio history from 07/04/2022 to 11/18/2026

Analytical breakdowns for Sarepta Therapeutics, Inc. (SRPT)

General company analysis:Sarepta, SRPT
Core merchandise of Sarepta Corp

The P/E ratio determines the market value of a business relative to its net income, allowing an investor to assess the premium paid for every dollar of earnings. By analyzing the current P/E valuation level, one can correlate the premium of Sarepta Therapeutics, Inc. (SRPT) shares with its exceptional position as a gene therapy leader, whose patent advantages and the complexity of RNA drug synthesis minimize the risks of competition from generics.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|TWST (twistbioscience.com) - P/E Multiple|10x Genomics, Inc. (TXG) - Business Payback Period|Price to Earnings Ratio NTLA (Intellia Therapeutics, Inc.)|STOK - Market Cap to Earnings|Price to Earnings Ratio biolifesolutions.com BLFS|Business Payback Period Wave Life Sciences Corp (WVE)|MAZE - Price to Earnings Ratio|Company Value to Net Income SION (Sionna Therapeutics Inc)|PRME: P/E Multiple|Taysha - Company Value to Net Income|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio